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Abstract 
Purpose 
To quantitatively compare retinal vascular characteristics over time in eyes eventually treated 
versus not treated for retinopathy of prematurity (ROP), using ROPtool analysis of narrow-field 
retinal images.  
Methods 
This longitudinal study used prospectively collected narrow-field retinal images of infants 
screened for ROP, prior to treatment, if needed. Images were analyzed using a methodology that 
combines quadrant-level measures from several images of the same eye. For the longitudinal 
analysis, one examination per postmenstrual age (PMA) was included per eye. We compared the 
following ROPtool indices and their change per week between eyes eventually treated versus not 
treated for ROP: tortuosity index (TI), dilation index (DI), sum of adjusted indices (SAI), and 
tortuosity-weighted plus (TWP). Analysis was performed on three levels: eye (mean value/eye), 
quadrant (highest quadrant value/eye), and blood vessel (highest blood vessel value/eye).  
Results 
Of 832 examinations (99 infants), 745 images (89.5%) had 3-4 quadrants analyzable by 
ROPtool. On the eye level, ROPtool indices differed between eyes eventually treated versus 
not treated at PMA of 33-35 and 37 weeks for TI, SAI, and TWP, and at PMA of 33-34 and 
37 weeks for DI (P ≤ 0.0014), and change per week differed between eyes eventually treated 
versus not treated only for SAI at PMA of 32 weeks (P < 0.001). 
Conclusions 
Quantitative analysis of retinal vascular characteristics using ROPtool can help predict eventual 
need for treatment for ROP as early as 32 weeks PMA. ROPtool index values were more useful 
than change in these indices to predict eyes that would eventually need treatment for ROP. 
  
Retinopathy of prematurity (ROP) is a leading cause of preventable childhood blindness in the 
United States.1 Every year, approximately 14,000-16,000 infants born in the United States 
(0.36%-0.41%) develop ROP and about 1,100-1,500 infants require treatment for ROP.2 
Appropriate screening and timely treatment can reduce the risk of childhood blindness due to 
ROP, and the decision to treat ROP usually depends on determining that plus disease is present.3 
However, the diagnosis of plus disease has been shown to be inconsistent even among experts.4 
Plus disease occurs when there is sufficient vascular dilation and tortuosity in ≥2 quadrants of 
the posterior pole compared to a standard photograph.5 To minimize subjectivity in assessing the 
presence of retinal vascular dilation and tortuosity, computer programs (eg, ROPtool, VesselMap, 
Computer-Aided Image Analysis of the Retina (CAIAR), Retiview, i-ROP) have been developed 
to quantitatively describe these vascular features in retinal images.  
ROPtool is a semiautomated computer program that calculates vessel dilation and 
tortuosity in retinal images.6 Although previous studies have shown that ROPtool has high 
sensitivity in identifying infants who will develop plus or pre-plus disease,7,8 its utility is limited 
by image quality.6,7 ROPtool cannot readily analyze images with poor focus and/or dark fundus 
pigmentation with poor contrast of the blood vessels.9 Previous studies using ROPtool have 
analyzed single retinal images to diagnose the presence of plus or pre-plus disease.8,10,11 More 
recently, a new technique combining quadrants from multiple narrow-field images of the same 
retina (ie, quadrant-level methodology) improved ROPtool’s ability to trace vessels and showed 
high accuracy in identifying plus or pre-plus disease among images of varying quality.12 
While most studies have evaluated ROPtool’s ability to identify the presence of plus or 
pre-plus disease at one point in time,8,12 two studies have used ROPtool to analyze vascular 
changes over time.13,14 One study found that as plus disease developed, changes in ROPtool 
tortuosity measures were sometimes very large, whereas changes in dilation measures were more 
subtle.13 Another study, which assessed the ability of ROPtool indices to predict which eyes may 
need treatment for ROP found that the highest mean tortuosity across all examinations was 
associated with need for treatment.14 When comparing the penultimate examination of eyes 
eventually needing treatment to the mean of all examinations of those not needing treatment, 
they found a trend toward increasing mean tortuosity with increasing postmenstrual age (PMA) 
among those eventually needing treatment.14 To date, no true longitudinal studies have been 
published that compare ROPtool analyses of eyes eventually treated versus not treated for ROP. 
The purpose of the current study was to longitudinally analyze narrow-field retinal images with 
ROPtool, using quadrant-level methodology to quantitatively compare ROPtool indices and 
change in these indices between eyes eventually treated and those not treated for ROP. 
Materials and Methods 
This study was approved by the Duke University and Cape Fear Valley Health System 
institutional review boards and conformed to the requirements of the US Health Insurance 
Portability and Accountability Act of 1996. 
Retinal images were prospectively collected by trained nonphysician health care workers 
(HCW) from infants (July 2014-April 2016) as part of a study evaluating the use of a Food and 
Drug Administration–approved portable, noncontact, narrow-field fundus camera (Pictor, Volk 
Optical Inc, Mentor, OH) to screen infants for ROP.15 In the previous study, nonphysician HCW 
selected ≤3 images per eye for each infant for each imaging session, aiming to show vessels in 
all 4 posterior pole quadrants. For the current study, sequentially acquired narrow-field retinal 
images from both eyes were included. If an eye was eventually treated for type 1 ROP (treatment 
group [TG]), we included all images from that eye prior to treatment, and if an eye was not 
treated for ROP (nontreatment group [NG]), we included all images. Additional data collected 
included birth weight, gestational age, ROP clinical findings, and whether/when ROP treatment 
occurred.  
ROPtool (v2.1.8) was used to trace images using the quadrant-level methodology.12 
Because ROPtool is a semiautomated computer program, user input was required to trace retinal 
images. Three investigators (two medical students [GJH, MCW] and one pediatric 
ophthalmology fellow [JCK]), all masked to clinical examination results, traced the images in a 
randomized order. For each eye, up to 3 images from the same session were used to select the 
quadrants with the best quality and most visible blood vessels, keeping the quadrants consistent 
among images from the same session to avoid duplicate tracing of a vessel in multiple quadrants. 
After it was determined which quadrants would be traced in which images, ROPtool was used to 
trace retinal vessels using the previously described quadrant-level methodology,12 aiming to trace 
up to 2 major retinal vessels per quadrant. A “traceable vessel” was defined as one that ROPtool 
could trace for a length of ≥1 optic disk diameter. Then, ROPtool calculated the following four 
indices of tortuosity, dilation, and combined tortuosity/dilation: 
1. Tortuosity index (TI): total length of vessel compared to length of a curve generated 
from equally spaced points on the vessel.6 
2. Dilation index (DI): average of the widths of multiple cross sections of a vessel.6 
3. Sum of adjusted indices (SAI): sum of DI and compressed TI.16 
4. Tortuosity-weighted plus (TWP): sum of adjusted TI and adjusted DI, which gives 
more weight to the TI.16 
For each eye, only one examination per PMA was included. PMA was divided into 
weekly intervals, by number of completed PMA in weeks (ie, PMA was rounded down). If 
imaging occurred more than once during a PMA interval (eg, at PMA of 36 weeks), the later 
examination was included. Because a diagnosis of plus disease requires ≥2 quadrants to have 
sufficient dilation and tortuosity, imaging sessions with images with fewer than 3 analyzable 
quadrants were excluded from the longitudinal analysis since plus disease could not be ruled out 
if the remaining quadrants were normal. 
SAS (v.9.4, SAS Institute Inc, Cary, NC) and R (v.3.6.1, R Foundation for Statistical 
Computing, Vienna, Austria) were used for all data analysis. We evaluated the number of 
analyzable quadrants, defined as having at least 1 traceable blood vessel. For our longitudinal 
analysis, images from each imaging session were included for all eyes, excluding any occurring 
after ROP treatment. We compared each ROPtool index and its change per week between eyes in 
the treatment versus nontreatment group at each weekly PMA interval using the nonparametric 
Wilcoxon rank-sum test. For each ROPtool index and its change per week, analysis was 
performed on three levels: eye (mean value/eye), quadrant (highest quadrant value/eye), and 
blood vessel (highest blood vessel value/eye). See Figure 1. Because several (ie, 24) comparisons 
were made, a Bonferroni correction was applied, and a P v lue of ≤0.0021 was considered 
statistically significant. For each PMA interval, receiver operating characteristic (ROC) curves 
were generated for each ROPtool index to determine cutoff values for maximizing sensitivity 
and specificity in identifying eyes in the treatment versus nontreatment group. Area under the 
ROC curves were calculated to quantify the usefulness of ROPtool as a diagnostic test. Among 
eyes eventually treated, ROPtool index cutoff values on the eye level were used to determine at 
what PMA each of these eyes would have been identified as being high-risk (ie, eventually 
needing treatment) versus low risk (ie, not needing treatment) by ROPtool and compared to the 
PMA at which these eyes were identified as needing treatment clinically.  
Results 
Our study included 198 eyes from 99 infants, with mean birthweight 918 g (range, 422–1644 g) 
and mean gestational age 26.9 weeks (range, 23.3-31.6). Treatment-requiring ROP developed in 
15 eyes (7.6%; 7 right and 8 left). 
Eye Examinations 
A total of 832 eye examinations were included in this study (Figure 2): 76 examinations 
performed prior to treatment for eyes in the treatment group and 756 for eyes in the nontreatment 
group. Of the 832 included examinations, mean PMA was 36.3 weeks (range, 30.9-51.4) overall, 
and 35.8 weeks (range, 33.4-38.7) when treatment-requiring ROP was identified. Each eye had a 
mean 4.2 examinations meeting inclusion criteria (range, 1-16). 
Analyzable Quadrants 
ROPtool could trace vessels in 3-4 quadrants in images from 745/832 (89.5%) imaging sessions 
(eSupplement 1, available at jaapos.org). There were 2996/3328 quadrants (90.0%) with ≥1 
traceable vessel.  
ROPtool Index and Change per Week Analysis 
We excluded 18 examinations of eyes with more than 1 examination at the same PMA 
interval, 87 with fewer than 3 analyzable quadrants, and 154 from the nontreatment group 
with a PMA of ≥39 weeks, because the latest PMA at which a decision was made to treat was 
38.7 weeks (Figure 2). Of the remaining 590 examination sessions, statistically significant (P 
≤ 0.0021) higher values for the following ROPtool indices were seen for treatment versus 
nontreatment eyes: TI all levels (ie, eye-, quadrant-, and blood vessel-analysis) at PMA of 33, 
35, and 37 weeks and eye level at PMA of 34 weeks (Figure 3A); DI all levels at PMA of 37 
weeks and eye level at PMA of 33 and 34 weeks; both SAI and TWP all levels at PMA of 
33-35 and 37 weeks (P ≤ 0.0014; Table 1).  
Change per week in ROPtool indices was statistically significantly different for 
treatment versus nontreatment eyes for the following ROPtool indices: TI blood vessel level 
at PMA of 32 and 37 weeks (Figure 3B), DI quadrant level at PMA of 32 weeks, and SAI 
eye and quadrant levels at PMA of 32 weeks and blood vessel level at PMA of 37 weeks (P < 
0.001; Table 1).  
Sensitivity, Specificity, and ROC Curves 
At each PMA interval, ROC curves were generated for each ROPtool index to determine cutoff 
values that maximized both sensitivity and specificity for identifying high-risk versus low-risk 
eyes at all levels. For each index, the cutoff values varied for each PMA interval (eSupplement 
2). At the eye level, the following ROPtool indices could identify high-risk eyes with 100% 
sensitivity: SAI at PMA of 31 weeks; TI at PMA of 35-38 weeks; and DI, SAI, and TWP at 
PMA of 37-38 weeks (eSupplement 2). Of eyes eventually treated for ROP, all ROPtool index 
cutoff values on the eye level were able to identify all eyes as being high risk either at the same 
or earlier PMA (mean, 2.8; range, 0-7.0 weeks earlier) compared to when these eyes were 
identified on clinical examination as needing treatment (eSupplement 3). 
Discussion 
Longitudinal analysis of narrow-field retinal images with ROPtool using quadrant-level 
methodology showed differences in tortuosity, dilation, and combination tortuosity/dilation 
measures at sequential weekly PMAs between treatment versus nontreatment eyes. Overall, 
ROPtool indices were higher for treatment versus non-treatment eyes as early as PMA of 33 
weeks on multiple levels (ie, eye, quadrant, and blood vessel; Table 1).  
By performing eye-, quadrant-, and blood vessel-level analysis, we could evaluate the 
importance of having just one abnormal (ie, tortuous or dilated) vessel versus more global 
assessments of quadrants and eyes. Since the eye level value is the average of all blood vessels in 
an eye, it should never be higher than the quadrant- or blood vessel-level value from the same 
eye. It was promising to see that eye level assessments performed well across all indices, 
indicating that a single blood vessel did not drive the differences found in our study (Table 1). 
Our results are consistent with a previous ROPtool study that found that higher mean TI 
(equivalent to our eye level TI) was associated with need for eventual treatment for ROP using a 
logistic regression model (Figure 3A).14 Of note, although this previous study found that neither 
highest mean DI (equivalent to our eye level DI) nor highest max DI (equivalent to our blood 
vessel level DI) was associated with need for eventual treatment for ROP,14 we found that DI had 
some predictive value for eyes eventually treated, particularly on the eye level (Table 1).  
In our study, the difference in change per week in ROPtool indices was less impressive 
than the difference in indices between treatment versus nontreatment eyes. Some studies have 
shown that rates of change in both tortuosity and dilation can help identify eyes at risk for 
treatment-indicated (type 1) ROP. One study using VesselMap to analyze vessels (arteriole 
versus venule) from superotemporal and inferotemporal quadrants of posterior pole images 
found that the change per week of mean venous diameter (similar to our eye level DI) had the 
best discriminative ability for treatment-indicated ROP.17 Another study using CAIAR to analyze 
the three widest vessels and three most tortuous vessels found that combining the rates of change 
(from first to last exam) of venular width and arteriolar tortuosity provided the best 
discriminative power for treatment-indicated versus nontreatment-indicated ROP.18 Our results 
showed that ROPtool index values were more useful than changes in ROPtool indices at 
identifying treatment eyes. This is consistent with a previous study that found no difference in 
the largest change per week in the following ROPtool indices between treatment versus non-
treatment eyes: mean (ie, eye level) or maximum (ie, blood vessel level) TI, DI, or SAI.14 
Using quadrant-level methodology,12 ROPtool could analyze (ie, trace at least 1 blood 
vessel for ≥1 disk diameter) 3-4 quadrants in 90% of our narrow-field retinal images 
(eSupplement 1). While an analysis of a subset of our data found that ROPtool could analyze 3-4 
quadrants in 98% of the narrow-field retinal images, this subset only included one examination 
per infant (the latest imaging session prior to treatment for those eventually treated for ROP, and 
the imaging session with the most severe posterior pole disease that was closest to PMA of 36 
for those not treated) with an average PMA of 35.6 weeks (range, 31.3-40.1; unpublished data) at 
the time those images were acquired.12 It was promising to see that ROPtool was able to analyze 
a high percentage of images when a wider range of PMAs were included (range, 30.9-51.4 
weeks), which more realistically simulates the PMAs when ROP screening occurs.  
Since severe ROP can have grave consequences if missed, the ideal screening test would 
have perfect sensitivity to identify infants with high-risk eyes and high enough specificity to 
minimize the number of examinations for infants with low-risk eyes. By performing a sensitivity 
analysis for each ROPtool index at each PMA interval (in weeks) maximizing sensitivity and 
specificity in identifying high-risk versus low-risk eyes, we found that cutoff values for each 
ROPtool index varied at each PMA (eSupplement 2). We found that one eye level ROPtool 
index was able to identify high-risk eyes with 100% sensitivity starting at a PMA of 31 weeks 
(eSupplement 2). While having perfect sensitivity is ideal in a screening test, the iterative nature 
of ROP screening might allow the screening test to miss a high-risk eye at the earliest PMA, as 
long as that test identifies the eye at a later PMA prior to clinical indication for treatment 
(usually type 1 ROP). For eyes that eventually developed treatment-requiring ROP, we found 
that using our list of possible eye level ROPtool index cutoff values, we would have picked up 
every eye eventually needing treatment prior (by 3 weeks on average) to being identified on 
clinical exam as needing treatment (eSupplement 3). Thus, we believe that the sensitivity of the 
screening test does not need to be 100% as long as the sensitivity of the repeated screening tests 
is 100%. 
The findings of this study should be viewed in light of some limitations. First, ROPtool 
could not analyze about 10% of images. Second, the number of treated eyes was much less than 
the number of untreated eyes. Despite this limitation, we were able to carry out our longitudinal 
analysis and see statistically significant differences between treatment versus nontreatment eyes. 
Although our study only included 15 (7.6%) eyes treated for ROP, this number is comparable to 
the 5%-10% of infants who require treatment for ROP.3,19-23 Because the oldest age for which 
any eye was treated for ROP in our cohort was at 38.7 weeks PMA, we could not perform 
longitudinal analysis beyond 38 weeks PMA. However, natural history data from the 
Cryotherapy for Retinopathy of Prematurity Study showed that infants with birth weights <1,251 
g developed threshold ROP at a median PMA of 37.3 weeks and thus should be captured in our 
analysis.24 Lastly, because ROPtool requires user input for vessel selection, its use is subject to 
interuser variability. However, a pilot study using ROPtool to quantify plus disease showed that 
interuser agreement between two experts was 95%, meaning ROPtool can have good reliability 
despite the need for user input.6  
We found that quantitative longitudinal analysis of retinal vascular characteristics using 
ROPtool can help predict eyes that eventually need treatment for ROP as early as 32 weeks PMA. 
To make ROPtool clinically useful, cutoff values for various ROPtool indices need to be 
validated using independent data sets. Automated analysis could be incorporated into a screening 
program utilizing non-contact imaging, which is less stressful to the infant than indirect 
ophthalmoscopy with scleral depression.25 Offering alternative screening strategies with 
noncontact imaging for low-risk infants and indirect ophthalmoscopy for high-risk infants could 
decrease the number of potentially physiologically stressful exams and reduce health care costs. 
References 
1. Shah PK, Prabhu V, Karandikar SS, Ranjan R, Narendran V, Kalpana N. Retinopathy of 
prematurity: past, present and future. World J Clin Pediatr 2016;5:35-46. 
2. National Eye Institute, NIH. Retinopathy of Prematurity.  https://www.nei.nih.gov/learn-
about-eye-health/eye-conditions-and-diseases/retinopathy-prematurity. Accessed March 4, 
2020. 
3.  Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications 
for the treatment of retinopathy of prematurity: results of the early treatment for 
retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684-94. 
4. Chiang MF, Jiang L, Gelman R, Du YE, Flynn JT. Interexpert agreement of plus disease 
diagnosis in retinopathy of prematurity. Arch Ophthalmol 2007;125:875-80. 
5.  International Committee for the Classification of Retinopathy of Prematurity. The 
International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 
2005;123:991-9. 
6. Wallace DK, Zhao Z, Freedman SF. A pilot study using “ROPtool” to quantify plus 
disease in retinopathy of prematurity. J AAPOS 2007;11:381-7. 
7. Wallace DK, Freedman SF, Zhao Z, Jung SH. Accuracy of ROPtool vs individual 
examiners in assessing retinal vascular tortuosity. Arch Ophthalmol 2007;125:1523-30. 
8. Vickers LA, Freedman SF, Wallace DK, Prakalapakorn SG. ROPtool analysis of images 
acquired using a noncontact handheld fundus camera (Pictor)--a pilot study. J AAPOS 
2015;19:570-2. 
9. Ahmad S, Wallace DK, Freedman SF, Zhao Z. Computer-assisted assessment of plus 
disease in retinopathy of prematurity using video indirect ophthalmoscopy images. Retina 
2008;28:1458-62. 
10. Wallace DK, Freedman SF, Hartnett ME, Quinn GE. Predictive value of pre-plus disease 
in retinopathy of prematurity. Arch Ophthalmol 2011;129:591-6. 
11. Kiely AE, Wallace DK, Freedman SF, Zhao Z. Computer-assisted measurement of retinal 
vascular width and tortuosity in retinopathy of prematurity. Arch Ophthalmol 
2010;128:847-52. 
12. Weinert MC, Wallace DK, Freedman SF, Riggins JW, Gallaher KJ, Prakalapakorn SG. 
ROPtool analysis of plus and pre-plus disease in narrow-field images: a multi-image 
quadrant-level approach. J AAPOS 2020;24:89.e1-89.e7 
13. Wallace DK, Freedman SF, Zhao Z. Evolution of plus disease in retinopathy of 
prematurity: quantification by ROPtool. Trans Am Ophthalmol 2009;107:47. 
14. Wu KY, Wallace DK, Freedman SF. Predicting the need for laser treatment in 
retinopathy of prematurity using computer-assisted quantitative vascular analysis. 
J AAPOS 2014;18:114-9. 
15. Prakalapakorn SG, Freedman SF, Hutchinson AK, et al. Evaluating a portable, 
noncontact fundus camera for retinopathy of prematurity screening by 
nonophthalmologist health care workers. Ophthalmol Retina 2018;2:864-71. 
16. Cabrera MT, Freedman SF, Kiely AE, Chiang MF, Wallace DK. Combining ROPtool 
measurements of vascular tortuosity and width to quantify plus disease in retinopathy of 
prematurity. J AAPOS 2011;15:40-44. 
17. Grunwald L, Mills MD, Johnson KS, et al. The rate of retinal vessel dilation in severe 
retinopathy of prematurity requiring treatment. Am J Ophthalmol 2009;147:1086-91.e2. 
18. Ghodasra DH, Thuangtong A, Karp KA, et al. The rate of change in retinal vessel width 
and tortuosity in eyes at risk for retinopathy of prematurity. J AAPOS 2012;16:431-6. 
19. Palmer EA, Flynn JT, Hardy RJ, et al. Incidence and early course of retinopathy of 
prematurity. Ophthalmology 1991;98:1628-40. 
20. Cryotherapy for Retinopathy of Prematurity Cooperative Group. The natural ocular 
outcome of premature birth and retinopathy: Status at 1 year. Arch Ophthalmol 
1994;112:903-12. 
21. Chiang MF, Arons RR, Flynn JT, Starren JB. Incidence of retinopathy of prematurity 
from 1996 to 2000: analysis of a comprehensive New York state patient database. 
Ophthalmology 2004;111:1317-25. 
22. Haines L, Fielder A, Scrivener R, Wilkinson AR; Royal College of Paediatrics and Child 
Health, the Royal College of Ophthalmologists and British Association of Perinatal 
Medicine. Retinopathy of prematurity in the UK I: the organisation of services for 
screening and treatment. Eye 2002;16:33-8. 
23. Binenbaum G, Bell EF, Donohue P, et al. Development of modified screening criteria for 
retinopathy of prematurity: primary results from the postnatal growth and retinopathy of 
prematurity study. JAMA Ophthalmol 2018;136:1034-40. 
24. Reynolds JD, Dobson V, Quinn GE, et al. Evidence-based screening criteria for 
retinopathy of prematurity: natural history data from the CRYO-ROP and LIGHT-ROP 
studies. Arch Ophthalmol 2002;120:1470-76. 
25. Prakalapakorn SG, Stinnett SS, Freedman SF, Wallace DK, Riggins JW, Gallaher KJ. 
Non-contact retinal imaging compared to indirect ophthalmoscopy for retinopathy of 
prematurity screening: infant safety profile. J Perinatol 2018;38:1266-9. 
  
Legends 
FIG 1. Analysis performed for each ROPtool index and its change per week on three levels: eye, 
quadrant, and blood vessel. A, Eye level analysis is the mean value of ≤8 blood vessels traced. B, 
Quadrant level is the highest of 4 quadrants values. C, Blood vessel level is the highest value of 
any 1 blood vessel. This blood vessel had the highest tortuosity index among all traceable blood 
vessels in this retinal image.  
FIG 2. Selection of eye examinations for inclusion in this study and for the longitudinal analysis. 
The treatment group (TG) consists of eyes eventually treated for retinopathy of prematurity 
(ROP); the nontreatment group (NG) consists of eyes not treated for ROP. Postmenstrual age 
(PMA) was divided into weekly intervals, by number of completed PMA in weeks. 
FIG 3. Box-and-whisker plots comparing tortuosity index (TI) for eyes eventually treated 
(treatment group [TG], prior to treatment) versus eyes not treated (nontreatment group [NG]) for 
retinopathy of prematurity. TI (A) and rate of change of TI (B) on the eye, quadrant, and blood 
vessel levels over postmenstrual age (PMA, weeks). Statistically significant (P ≤ 0.0021, denoted 
by *) higher values of TI were seen for eyes in TG versus NG on all levels at PMA of 33, 35, and 
37 weeks and on the eye level at PMA of 34 weeks (A). Statistically significant (P ≤ 0.0021, 
denoted by *) change in TI per week in eyes in TG versus NG on the blood vessel level at PMA 
of 32 and 37 weeks. The box-and-whiskers plots show the lower (25%) and upper (75%) 
quartiles and the median. The bottom whisker represents the 25% quartile – (1.5 × interquartile 
range), and the top whisker represents the 75% quartile + (1.5 × interquartile range). The 
interquartile range is the difference between the 75% quartile and the 25% quartile. Data falling 
outside the interquartile range are plotted as diamond-shaped points and are considered as 
outliers of the data. 
Table 1. Comparison of ROPtool Indices and their change per week between eyes eventually treated versus not treated for retinopathy of prematurity 
 
Group PMA, weeks TI DI SAI TWP 
Ea Qb BVc Ea Qb BVc Ea Qb BVc Ea Qb BVc 
TGd NGe P valuef 
11 55 31 0.076 0.25 0.37 0.22 0.058 0.16 0.53 0.42 0.25 0.11 0.21 0.38 
12 34 32 0.029 0.054 0.013 0.99 0.46 0.39 0.077 0.011 0.025 0.023 0.065 0.017 
10 75 33 <0.001 <0.001 <0.001 0.0014 0.0086 0.0090 <0.001 0.0014 0.0010 <0.001 <0.001 <0.001 
10 64 34 0.0010 0.0045 0.011 <0.001 0.0028 0.0033 <0.001 <0.001 0.0013 <0.001 <0.001 <0.001 
9 104 35 <0.001 <0.001 <0.001 0.029 0.072 0.18 <0.001 <0.001 0.0013 <0.001 <0.001 <0.001 
5 63 36 0.011 0.017 0.036 0.0026 0.078 0.13 0.0028 0.0068 0.0048 0.0030 0.0073 0.0041 
7 74 37 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
2 53 38 0.040 0.12 0.10 0.018 0.018 0.018 0.020 0.023 0.023 0.023 0.023 0.050 
Group PMA, weeks Change per week of  
TI 
Change per week of  
DI 
Change per week of  
SAI 
Change per week of  
TWP 
Ea Qb BVc Ea Qb BVc Ea Qb BVc Ea Qb BVc 
TGd NGe P valuef 
0 2 31 — — — — — — — — — — — — 
11 51 32 0.046 0.021 <0.001 0.017 <0.001 0.0042 <0.001 <0.001 0.0057 0.0084 0.065 0.0079 
12 30 33 0.77 0.59 0.0079 0.012 0.10 0.14 0.014 0.12 0.048 0.10 0.38 0.048 
6 65 34 0.46 0.50 0.84 0.21 0.35 0.99 0.58 0.55 0.59 0.039 0.013 0.11 
8 56 35 0.30 0.17 0.11 0.60 0.30 0.66 0.76 0.94 0.94 0.79 0.49 0.84 
7 72 36 0.34 0.23 0.17 0.88 0.89 0.82 0.99 1.0 0.28 1.0 0.72 0.28 
5 44 37 0.043 0.050 <0.001 0.15 0.41 0.18 0.016 0.029 <0.001 0.0065 0.11 0.0038 
2 44 38 0.93 0.069 0.081 0.0077 0.0019 0.030 0.030 0.048 0.43 0.15 0.37 0.55 
BV, blood vessel-level; DI, dilation index; E, eye level; NG, nontreatment group; PMA, postmenstrual age; SAI, sum of adjusted indices; TG, treatment group; TI, 
tortuosity index; TWP, tortuosity weighted-plus; Q, quadrant level.  
aEye level is the mean value per eye. 
bQuadrant level is the highest quadrant value per eye. 
cBlood vessel level is the highest value from any blood vessel per eye. 
dTreatment group was made up of eyes eventually treated for ROP; it included all imaging sessions prior to treatment.  
eNontreatment group was made up of eyes not treated for ROP; it included all imaging sessions. 
fP values calculated using Wilcoxon rank-sum test. Statistically significant P values indicate higher values seen for eyes in the treatment versus nontreatment 
group, P ≤ 0.0021. 



